In preclinical studies, RC48 demonstrated greater efficacy than trastuzumab and lapatinib against HER-2-overexpressing breast cancer cells and showed a greater antitumoral effect than T-DM1 in trastuzumab- and lapatinib-resistant tumor cells [102]. This evidence concerns the gene ERBB2 and neoplasm.